242 related articles for article (PubMed ID: 24462743)
1. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
[TBL] [Abstract][Full Text] [Related]
2. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Cutler CS; Bhuiya NS; Schowalter M; Ho VT; Alyea EP; Koreth J; Blazar BR; Soiffer RJ; Antin JH; Ritz J
Blood; 2009 Apr; 113(16):3865-74. PubMed ID: 19168788
[TBL] [Abstract][Full Text] [Related]
3. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
Allen JL; Fore MS; Wooten J; Roehrs PA; Bhuiya NS; Hoffert T; Sharf A; Deal AM; Armistead P; Coghill J; Gabriel DA; Irons R; Essenmacher A; Shea TC; Richards K; Cutler C; Ritz J; Serody J; Baldwin AS; Sarantopoulos S
Blood; 2012 Sep; 120(12):2529-36. PubMed ID: 22896003
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
5. B cells in chronic graft-versus-host disease.
Sarantopoulos S; Blazar BR; Cutler C; Ritz J
Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
[TBL] [Abstract][Full Text] [Related]
6. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.
Jia W; Poe JC; Su H; Anand S; Matsushima GK; Rathmell JC; Maillard I; Radojcic V; Imai K; Reyes NJ; Cardona DM; Li Z; Suthers AN; Curry-Chisolm IM; DiCioccio RA; Saban DR; Chen BJ; Chao NJ; Sarantopoulos S
Blood; 2021 May; 137(18):2544-2557. PubMed ID: 33534893
[TBL] [Abstract][Full Text] [Related]
7. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J
Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.
Fedoriw Y; Samulski TD; Deal AM; Dunphy CH; Sharf A; Shea TC; Serody JS; Sarantopoulos S
Biol Blood Marrow Transplant; 2012 Jun; 18(6):968-73. PubMed ID: 22446015
[TBL] [Abstract][Full Text] [Related]
9. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
Front Immunol; 2020; 11():1505. PubMed ID: 32849514
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
[TBL] [Abstract][Full Text] [Related]
11. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
12. Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity.
Hillhouse EE; Thiant S; Moutuou MM; Lombard-Vadnais F; Parat R; Delisle JS; Ahmad I; Roy DC; Guimond M; Roy J; Lesage S
Biol Blood Marrow Transplant; 2019 Jan; 25(1):19-25. PubMed ID: 30244108
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
15. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
17. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
18. No impact of total or myeloid Cd34+ cell numbers on neutrophil engraftment and transplantation-related mortality after allogeneic pediatric bone marrow transplantation.
Pichler H; Witt V; Winter E; Boztug H; Glogova E; Pötschger U; Matthes-Martin S; Fritsch G
Biol Blood Marrow Transplant; 2014 May; 20(5):676-83. PubMed ID: 24492145
[TBL] [Abstract][Full Text] [Related]
19. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Bhuiya NS; Cutler CS; Soiffer RJ; Antin JH; Ritz J
Clin Cancer Res; 2007 Oct; 13(20):6107-14. PubMed ID: 17947475
[TBL] [Abstract][Full Text] [Related]
20. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
